- Home
- BCAB vs CRIS Comparison
BCAB vs CRIS Comparison
Compare BCAB & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- CRIS
- Stock Information
- Founded
- BCAB 2007
- CRIS 2000
- Country
- BCAB United States
- CRIS United States
- Employees
- BCAB N/A
- CRIS N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAB Health Care
- CRIS Health Care
- Exchange
- BCAB Nasdaq
- CRIS Nasdaq
- Market Cap
- BCAB 19.9M
- CRIS 21.3M
- IPO Year
- BCAB 2020
- CRIS 2000
- Fundamental
- Price
- BCAB $0.33
- CRIS $1.63
- Analyst Decision
- BCAB Buy
- CRIS Strong Buy
- Analyst Count
- BCAB 2
- CRIS 2
- Target Price
- BCAB $1.00
- CRIS $16.50
- AVG Volume (30 Days)
- BCAB 811.8K
- CRIS 130.8K
- Earning Date
- BCAB 08-11-2025
- CRIS 08-05-2025
- Dividend Yield
- BCAB N/A
- CRIS N/A
- EPS Growth
- BCAB N/A
- CRIS N/A
- EPS
- BCAB N/A
- CRIS N/A
- Revenue
- BCAB $11,000,000.00
- CRIS $11,202,000.00
- Revenue This Year
- BCAB N/A
- CRIS N/A
- Revenue Next Year
- BCAB N/A
- CRIS $9.52
- P/E Ratio
- BCAB N/A
- CRIS N/A
- Revenue Growth
- BCAB N/A
- CRIS 14.17
- 52 Week Low
- BCAB $0.24
- CRIS $1.02
- 52 Week High
- BCAB $2.53
- CRIS $8.29
- Technical
- Relative Strength Index (RSI)
- BCAB 38.71
- CRIS 34.22
- Support Level
- BCAB $0.33
- CRIS $1.68
- Resistance Level
- BCAB $0.37
- CRIS $1.88
- Average True Range (ATR)
- BCAB 0.04
- CRIS 0.12
- MACD
- BCAB -0.00
- CRIS -0.01
- Stochastic Oscillator
- BCAB 5.26
- CRIS 17.14
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.